Press Releases

Date Title and Summary Additional Formats
Toggle Summary Harvard Bioscience to Present at Sidoti Investor Conference March 22-23, 2023
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Virtual Investor Conference taking place on March 22-23, 2023. Mr.
View HTML
Toggle Summary Harvard Bioscience to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March
View HTML
Toggle Summary Harvard Bioscience Announces Fourth Quarter 2022 Financial Results
HOLLISTON, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period,
View HTML
Toggle Summary Harvard Bioscience Schedules Fourth Quarter 2022 Earnings Conference Call for March 9, 2023 at 8:00 AM ET 
HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2022 before the market opens on March 9, 2023, and will hold a conference call to discuss the results at 8:00 a.m.
View HTML
Toggle Summary Harvard Bioscience Announces CFO Transition
HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company’s chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer Cote, the Company’s vice
View HTML
Toggle Summary Harvard Bioscience Announces Third Quarter 2022 Financial Results
 “Fighting through challenging times while building the company and new technologies for the future.” HOLLISTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2022.
View HTML
Toggle Summary Harvard Bioscience Schedules Third Quarter 2022 Earnings Conference Call for November 8, 2022 at 4:30 PM ET
HOLLISTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2022 after the market closes on November 8, 2022, and will hold a conference call to discuss the results at 4:30 p.m.
View HTML
Toggle Summary Harvard Bioscience Announces Second Quarter 2022 Financial Results
HOLLISTON, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2022. Jim Green, Chairman and CEO, said, "Our second quarter revenues were essentially flat compared to the prior year
View HTML
Toggle Summary Harvard Bioscience Schedules Second Quarter 2022 Earnings Conference Call for August 4, 2022 at 8:00 AM ET
HOLLISTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2022 before the market opens on August 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m.
View HTML
Toggle Summary Harvard Bioscience Announces First Quarter 2022 Financial Results
Revenue up 7 % year-over-year despite volatility in China related to COVID-19 and global supply chain headwinds HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31,
View HTML